| How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice SR Hanney, S Castle-Clarke, J Grant, S Guthrie, C Henshall, ... Health research policy and systems 13, 1-18, 2015 | 209 | 2015 |
| Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom J Sussex, Y Feng, J Mestre-Ferrandiz, M Pistollato, M Hafner, P Burridge, ... BMC medicine 14, 1-23, 2016 | 79 | 2016 |
| European Union pharmaceutical markets: a case for differential pricing? A Towse, M Pistollato, J Mestre-Ferrandiz, Z Khan, S Kaura, L Garrison International Journal of the Economics of Business 22 (2), 263-275, 2015 | 42 | 2015 |
| Association between market concentration of hospitals and patient health gain following hip replacement surgery Y Feng, M Pistollato, A Charlesworth, N Devlin, C Propper, J Sussex Journal of Health Services Research & Policy 20 (1), 11-17, 2015 | 30 | 2015 |
| Multi-indication pricing: pros, cons and applicability to the UK J Mestre-Ferrandiz, R Dellamano, M Pistollato, A Towse Seminar briefing, 2015 | 25 | 2015 |
| How should public health recommendations address Lp (a) measurement, a causative risk factor for cardiovascular disease (CVD)? AL Catapano, M Daccord, E Damato, SE Humphries, RDG Neely, ... Atherosclerosis 349, 136-143, 2022 | 13 | 2022 |
| Understanding variations in relative effectiveness: A health production approach A Towse, B Jonsson, C McGrath, A Mason, R Puig-Peiro, ... International journal of technology assessment in health care 31 (6), 363-370, 2015 | 13 | 2015 |
| An international comparative analysis and roadmap to sustainable biosimilar markets KA Alnaqbi, A Bellanger, A Brill, G Castañeda-Hernández, ... Frontiers in Pharmacology 14, 1188368, 2023 | 4 | 2023 |
| The consequences of greater Net Price Transparency for innovative medicines in Europe: Searching for a consensus P Bentata, M Czech, W Greiner, W Groot, P Gyger, J Marques-Gomes, ... DOI: 10.13140/RG.2.2.27978.80320/1, 2020 | 4* | 2020 |
| A policy call to address rare kidney disease in health care plans R Vanholder, R Coppo, WJW Bos, E Damato, F Fakhouri, A Humphreys, ... Clinical Journal of the American Society of Nephrology 18 (11), 1510-1518, 2023 | 3 | 2023 |
| Biosimilars: a global roadmap for policy sustainability T Wilsdon, M Pistollato, K Ross-Stewart, R Saada, P Barquin, KA Alnaqbi, ... Charles River Associates, 2022 | 3 | 2022 |
| Market penetration and Receiving Party Pays regime T Majer, M Pistollato Working Paper, 2012 | 3 | 2012 |
| SM2 the consequences of greater net price transparency for innovative medicines in europe: insights from a multi-agent simulation model W Van Dyck, M Riccaboni, T Swoboda, M Pistollato Value in Health 24, S241, 2021 | 1 | 2021 |
| Multi-Indication Pricing: Pros, Cons, And Its Applicability To The United Kingdom J Mestre-Ferrandiz, A Towse, R Dellamano, M Pistollato Value in Health 19 (3), A8, 2016 | 1 | 2016 |
| HPR94 Treating Early Often Comes Too Late: Ensuring Patient Access to Early Cancer Detection and Treatment in Europe C Capdevila, M Pistollato, T Krueger, A Roediger, R Gilardino Value in Health 26 (12), S270, 2023 | | 2023 |
| HPR97 Healthcare Systems Resilience and the COVID-19 Emergency: How Care Can Be Improved Within the Current Budget and Resources Constraint by Increasing the Efficiency of … H Ahir, M Pistollato Value in Health 26 (12), S271, 2023 | | 2023 |
| P30 Do Novel Oncology Combination Therapies Have a Place Within the EU Legislative Framework? The Impact of Challenges for Novel Combination Therapies on Equality of Access … M Pistollato, T Veale, SJ Ong Value in Health 26 (12), S8, 2023 | | 2023 |
| 1348P The main challenges and potential solutions to improving patient access to oncology combination therapies in Europe M Pistollato, T Wilsdon, C Poon, T Veale Annals of Oncology 33, S1155-S1156, 2022 | | 2022 |
| POSC216 How Should Public Health Recommendations Address LP (A), a Causative Risk Factor for Cardiovascular Disease (CVD)? AL Catapano, M Daccord, E Damato, SE Humphries, DG Neely, ... Value in Health 25 (1), S150, 2022 | | 2022 |
| The Role of TRIPS in Encouraging Diffusion of Pharmaceutical Technology to Developing Countries IM Cockburn, T Wilsdon, M Pistollato, R Jayasuriya, T Watson Available at SSRN 3990215, 2021 | | 2021 |
